The possibility of targeting IL-15 signaling in liver fibrosis remains to be tested, and should take into consideration that IL-15 treatment has been shown to be beneficial in kidney and pancreatic fibrosis models, possibly via reducing TGFβ production and its profibrotic functions by unknown mechanisms (72–75). This evidence concerns the gene TGFB1 and Hepatic fibrosis.